Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pediatrix Medical Group, Inc.MD · Entity 4451 | Director · Chief Executive Officer | August 30, 2024 | September 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pediatrix Medical Group, Inc.
Report date August 30, 2024 · Filed September 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 170,001 |
Reported balance
After 2024-08-30 transaction · row 1
1 source rowRow 1 · 2024-08-30 · Sale · Disposed 11,100 · Balance 170,001 F1: The price reported in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $10.71 to $11.00 for a weighted average sales price of $10.79. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $10.71 to $11.00 for a weighted average sales price of $10.79. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2024 Filed Sep 3, 2024 21:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 11,100 | $10.79 | $119,769.00 |
DisclosureSEC source: 0000950170-24-102887 · ownership.xml · nonDerivative · entry 1 Swift James D · CIK 0001926690 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,001 F1 · price: The price reported in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $10.71 to $11.00 for a weighted average sales price of $10.79. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 21:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 105,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068809 · ownership.xml · nonDerivative · entry 1 Swift James D · CIK 0001926690 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,101 F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2025, twenty-five percent (25%) of the restricted shares will vest on June 1, 2026 and fifty percent (50%) of the restricted shares will vest on June 1, 2027, subject to the terms of the Plan. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Tax withholdingCommon Stock | 14,938 | $9.15 | $136,682.70 |
DisclosureSEC source: 0001209191-24-004394 · doc4.xml · nonDerivative · entry 1 Swift James D · CIK 0001926690 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,936 F1 · kind: Represents 14,938 restricted shares withheld for payment of taxes upon vesting of shares. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 5,764 | $9.58 | $55,219.12 |
DisclosureSEC source: 0001209191-23-058799 · doc4.xml · nonDerivative · entry 1 Swift James D · CIK 0001926690 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,874 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 13,193 | $14.14 | $186,549.02 |
DisclosureSEC source: 0001209191-23-037952 · doc4.xml · nonDerivative · entry 1 Swift James D · CIK 0001926690 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,638 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $14.02 to $14.40 for a weighted average sales price of $14.14. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:01 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Tax withholdingCommon Stock | 9,909 | $15.74 | $155,967.66 |
DisclosureSEC source: 0001209191-23-015674 · doc4.xml · nonDerivative · entry 2 Swift James D · CIK 0001926690 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,831 F3 · kind: Represents 9,909 restricted shares withheld for payment of taxes upon vesting of shares. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:01 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 49,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015674 · doc4.xml · nonDerivative · entry 1 Swift James D · CIK 0001926690 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,740 F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2024, twenty-five percent (25%) of the restricted shares will vest on March 1, 2025 and fifty percent (50%) of the restricted shares will vest on March 1, 2026, subject to the terms of the Plan. F2 · balance_after: Excludes 17,974 previously reported shares of restricted common stock granted to the reporting person pursuant to the Plan in connection with an annual equity award that were forfeited because the performance-based criteria were not achieved. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:14 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 24,000 | $15.31 | $367,440.00 |
DisclosureSEC source: 0001209191-22-056208 · doc4.xml · nonDerivative · entry 1 Swift James D · CIK 0001926690 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,956 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $15.20 to $15.43 for a weighted average sales price of $15.31. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.